SciCombinator

Discover the most talked about and latest scientific content & concepts.

MDMA-Assisted Therapy: A New Treatment Paradigm for Autistic Adults with Social Anxiety

OPEN Progress in neuro-psychopharmacology & biological psychiatry | 31 Mar 2015

AL Danforth, CM Struble, B Yazar-Klosinski, CS Grob and AL Danforth
Abstract
The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014. The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population. Serious Adverse Events (SAEs) involving administration of MDMA in clinical trials have been rare and non-life threatening. To date, MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations. Now that safety parameters for limited use of MDMA in clinical settings have been established, a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population. As in the case with classic hallucinogens and other psychedelic drugs, MDMA catalyzes shifts towards openness and introspection that do not require ongoing administration to achieve lasting benefits. This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA, which may provide a significant advantage over medications that require daily dosing. Consequently, clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol.
Tweets*
185
Facebook likes*
17
Reddit*
4
News coverage*
17
Blogs*
5
SC clicks
0
Concepts
Clinical psychology, Serotonin, Psychedelic drug, Clinical research, Psychedelics, dissociatives and deliriants, Psychotherapy, Adverse event, Clinical trial
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com